







an Open Access Journal by MDPI

# **Human Papillomavirus, Vaccines and Women's Health**

Guest Editor:

#### Dr. Marco Petrillo

Gynecologic and Obstetric Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy

Deadline for manuscript submissions:

closed (31 March 2022)

### Message from the Guest Editor

Dear Colleagues,

The main objective of this Special Issue is to provide novel interesting insights regarding HPV vaccination and its potential implications for women's health of HPV vaccination to the scientific community, moving from primary and secondary prevention of cervical dysplasia and vulvar/anal condylomas to other non-gynecological issues including proctological diseases, head & neck and lung malignancies, as well as HPV-related couple fertility problems. Furthermore, we especially welcome original research papers and review articles providing high-quality rigorous novel insights regarding biological issues related to HPV vaccination (cross-protection, mechanisms of immunological escape, etc.), as well as epidemiological and community studies investigating the issues of HPV vaccination initiatives all over the world.

With the hope of an enthusiastic participation of the scientific community, we launch here the *Vaccines* Special Issue entitled: "Human Papillomavirus, Vaccines and Women's Health."













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

## **Message from the Editor-in-Chief**

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### **Author Benefits**

**Open Access:** free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### **Contact Us**